Fibroblast growth factor-21 is a promising dietary restriction mimetic

Rejuvenation Research

Volumn 15, Issue 6, 2012, Pages 624-628

  Mendelsohn, Andrew R ^a   Larrick, James W ^a  

^a Panorama Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE PHOSPHATE; BUTYRIC ACID; FATTY ACID; FENOFIBRATE; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GROWTH HORMONE; LIPID; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SOMATOMEDIN C;

DIET RESTRICTION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN SENSITIVITY; LIFESPAN; LONGEVITY; MAMMAL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STARVATION;

ANIMALS; CALORIC RESTRICTION; FIBROBLAST GROWTH FACTORS; HEALTH; HUMANS; LONGEVITY;

ANIMALIA; MAMMALIA; MUS MUSCULUS; PRIMATES; RODENTIA;

EID: 84872726325     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2012.1392     Document Type: Review

References (27)

1. Mendelsohn AR, Larrick JW. Dietary restriction: Critical co-factors to separate health span from life span benefits. Rejuvenation Res 2012;15:523-529.
2. Mouchiroud L, Molin L, Dalliere N, Solari F. Life span extension by resveratrol, rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging. Biofactors 2010;36:377-382.
3. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: From pharmacology to physiology. Am J Clin Nutr 2010;91: 254S-257S.
4. Ge X, Wang Y, Lam KS, Xu A. Metabolic actions of FGF21: Molecular mechanisms and therapeutic implications. Acta Pharmaceutica Sinica B 2012;2:350-357.
5. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008;8: 77-83.
6. Kubicky RA, Wu S, Kharitonenkov A, De Luca F. Role of fibroblast growth factor 21 (FGF21) in undernutritionrelated attenuation of growth in mice. Endocrinology 2012; 153:2287-2295.
7. Zhang Y, Xie Y, Berglund ED, Coate KC, He TT, Katafuchi T, Xiao G, Potthoff MJ, Wei W, Wan Y. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife 2012;1.
8. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007;5:415-425.
9. Barclay JL, Nelson CN, Ishikawa M, Murray LA, Kerr LM, McPhee TR, Powell EE, Waters MJ. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011;152:181-192.
10. Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, Goetz R, Mohammadi M, Gerard RD, Dechow PC, Mangelsdorf DJ, Kliewer SA, Wan Y. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor c. Proc Natl Acad Sci USA 2012;109:3143-3148.
11. Belfiore A, Genua M, Malaguarnera R. PPAR-c agonists and their effects on IGF-I receptor signaling: Implications for cancer. PPAR Res 2009;2009.
12. Trepanowski JF, Canale RE, Marshall KE, Kabir MM, Bloomer RJ. Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: A summary of available findings. Nutr J 2011;10:107.
13. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by pparalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007;5:426-437.
14. Ga?lman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstro?m I, Dahlin M, Amark P, Angelin B, Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008;8:169-174.
15. Li H, Gao Z, Zhang J, Ye X, Xu A, Ye J, Jia W. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 2012;61:797-806.
16. Reolon GK, Maurmann N, Werenicz A, Garcia VA, Schro?der N, Wood MA, Roesler R. Posttraining systemic administration of the histone deacetylase inhibitor sodium butyrate ameliorates aging-related memory decline in rats. Behav Brain Res 2011;221:329-332.
17. McDonald P, Maizi BM, Arking R. Chemical regulation of mid- and late-life longevities in drosophila. Exp Gerontol 2012; http://dx.doi.org/10.1016/j. exger.2012.09.006/.
18. Nygaard EB, Vienberg SG, Ørskov C, Hansen HS, Andersen B. Metformin stimulates FGF21 expression in primary hepatocytes. Exp Diabetes Res 2012;2012:1-8.
19. Dhahbi JM, Mote PL, Fahy GM, Spindler SR. Identification of potential caloric restriction mimetics by microarray profiling. Physiol Genomics 2005;23:343-350.
20. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Kovalenko IG, Poroshina TE. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011;3:148-157.
21. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, others. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008;7:2769-2773.
22. Jang WG, Kim EJ, Bae I-H, Lee K-N, Kim YD, Kim D-K, Kim S-H, Lee C-H, Franceschi RT, Choi H-S, Koh J-T. Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of runx2. Bone 2011;48: 885-893.
23. Jeyabalan J, Shah M, Viollet B, Chenu C. AMP-activated protein kinase pathway and bone metabolism. J Endocrinol 2011;212:277-290.
24. Narkar VA, Downes M, Yu RT, Embler E, Wang Y-X, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARd agonists are exercise mimetics. Cell 2008;134:405-415.
25. Bueno Jú nior CR, Pantalea?o LC, Voltarelli VA, Bozi LHM, Brum PC, Zatz M. Combined effect of AMPK/PPAR agonists and exercise training in mdx mice functional performance. PLoS One 2012;7:e45699.
26. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, Ge H, Weiszmann J, Lu S-C, Graham M, Busby J, Hecht R, Li Y-S, Li Y, Lindberg R, Ve'niant MM. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models - association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009;297:E1105-E1114.
27. Huang Z, Wang H, Lu M, Sun C, Wu X, Tan Y, Ye C, Zhu G, Wang X, Cai L, Li X. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS One 2011;6:e20669.